Invest in PlantForm
Investment opportunities are available as PlantForm commercializes its plant-based biopharmaceutical platform.
PlantForm has succeeded in raising $2 million in funding from its founders and angel investors, and is currently raising $10 million in equity to advance its biosimilar trastuzumab product to completion of Phase I human clinical trials in 2014.
Learn more about the biopharmaceutical market.
For more information, please contact:
President and CEO
"PlantForm is ideally positioned to meet the fast-growing demand for affordable antibody medicines: it has a novel, versatile and scalable manufacturing platform with an excellent management team that can execute on a well thought-out plan."
President & CEO, Dalton Chemical Laboratories Inc.